Fibronectin receptors of phagocytes. Characterization of the Arg-Gly- Asp binding proteins of human monocytes and polymorphonuclear leukocytes by unknown
FIBRONECTIN RECEPTORS OF PHAGOCYTES
Characterization ofthe Arg-Gly-Asp Binding Proteins of Human
Monocytes and Polymorphonuclear Leukocytes
BY ERIC J. BROWN AND JENNIFER L. GOODWIN
From the Division ofInfectious Diseases, the Department ofMedicine and the Department of
Microbiology and Immunology, Washington University School ofMedicine,
St. Louis, Missouri 63110
The process of receptor-mediated ingestion is a regulated function of phago-
cytes . Phagocytosis of both complement and IgG opsonized targets can be
enhanced by T cell-derived cytokines (1, 2), andcomplement receptor-mediated
ingestion also can be markedly influenced by tumor-promoting phorbol esters
(3) . Work over the past several years has suggested that extracellular matrix
proteins such as fibronectin (Fn),' laminin, and serum amyloid P component may
be physiologic regulators of phagocytosis by both monocytes and Polymorpho-
nuclear leukocytes (PMN) (4-7) . Exposure ofmonocytes to these matrix proteins
will enhance phagocytosis via both IgG Fc receptors and complement receptors .
ForPMN, the effect ofbinding to the extracellular matrix on phagocytic function
is more complex . Although Fn binds to unactivated PMN, it enhances comple-
ment receptor-mediated phagocytosis only after the cells have been exposed to
an activating agent, such as the bacterial peptide FMLP or the complement-
derived chemotaxin C5a . The reason for the different responses of the two
phagocytic cell types to Fn is unknown . Previous indirect evidence suggested
that the Fn receptors on the two cells were quite similar, since they recognized
the same domain of Fn, and since Fn bound to both cells with similar affinity (6) .
Although the number of Fn receptors differed between PMN and monocytes,
our previous data showed that this could not explain the difference in respon-
siveness of the two cell types, since FMLP and C5a did not alter Fn binding to
thePMN . Binding ofFn to both monocytes and PMN was blocked by two mAbs,
M1/70 and A6F10 (8), again suggesting a close relationship between the Fn
receptors of the two phagocytic cells .
Recently, much progress has been made in understanding the Fn receptors on
a variety of different cells (9-14) . These investigations have shown that there
are at least two distinct types of cellular Fn receptors, both of which recognize
theamino acid sequenceArg-Gly-Asp (RGD), contained within Fn . One receptor,
found initially in fibroblasts, binds to Fn but not other RGD-containing proteins .
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￿
CBD, chymotryptic cell binding domain of fibronectin; Fn,
fibronectin ; NPGB, parsnitrophenyl paraguanidino benzoate ; PMN, Polymorphonuclear leukocytes ;
vWF, von Willebrand's Factor .
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The second receptor, found on platelets, recognizes the RGD sequence in a
variety of otherwise unrelated proteins such as fibrinogen, von Willebrand's
factor (vWF), and vitronectrin (15, 16). While the fibroblast Fn receptor will
bind to an enzyme-derived fragment of Fn but not to small synthetic peptides,
the platelet receptor binds to the synthetic peptides with high affinity. While the
two receptors both consist of two noncovalently linked polypeptide chains, the
molecular weights of both chains differ between the two receptors. Despite these
differences, the receptor proteins are structurally related to each other and also
to the Mac-1, LFA-1, p(150,95) family of leukocyte surface molecules (17, 18).
In this work, we have studied the RGD receptors of PMN and monocytes in
order to understand the functional and structural features of the Fn receptors
of the two cell types. We have discovered significant differences between the
RDG receptors of these cells and previously described Fn receptors. Monocytes
have both fibroblastlike and plateletlike Fn receptors. In contrast, PMN have
only a single type of receptor, related to the platelet RGD binding protein.
However, structural and functional data suggest that the plateletlike receptors
expressed by both monocytes and PMN are not identical to gp IIb/IIIa, the Fn
receptor of platelets. These new receptors, unique to phagocytes, are required
for the stimulatory effect of Fn and other RGD-containing proteins on ingestion
of opsonized particles.
Materials and Methods
Buffers.
￿
Cell solubilization buffer (bufferA): PBS buffer containing 200 mM octylglu-
coside, 20 mM iodoacetamide, 2 pM pepstatin, 2 uM leupeptin, 25 PM paranitrophenyl
paraguanidinobenzoate (NPGB), 1 mM CaC12, and I MM MgC12, pH 7.4; Column buffer
(buffer B): PBS containing 10 mM Chaps, 1 mM CaC12, 1 MM MgC12,and 25 P,M NPGB,
pH 7.4; Elution buffer (buffer C): PBS containing 10 mM Chaps, 10 mM EDTA, and 25
juM NPGB, pH 7.4.
Proteins and Peptides.
￿
Fn and the chymotryptic cell binding domain (CBD) of 105-
110kD were prepared as described(19). Collagen type IV was the kind gift of Dr. Hynda
Kleinmann, National Institute of Dental Research, Bethesda, MD. vWF was thekind gift
of Dr. Sam Santoro or Dr. Evin Sadler, Washington University School of Medicine.
Fibrinogen was purchased from Sigma Chemical Co., St. Louis, MO, and vitronectin was
from Calbiochem-Behring Corp., La Jolla, CA. The synthetic peptides KYAVTGRGDS
and CYAVTGRGDS were gifts from Dr. Steve Adams, Monsanto Corp., St. Louis, MO.
The sequence YAVTGRGDS is present within the cell binding domain of human Fn (20,
21). The peptide GRGDSP was purchased from Peninsula Laboratories, Inc., Belmont,
CA. The chymotryptic CBD and KYAVTGRGDS were bound to CNBr-activated Seph-
arose (Pharmacia Fine Chemicals, Piscataway, NJ) at 3-5 mg/ml. These are called CBD-
Sepharose and peptide-Sepharose, respectively. All proteins were assessed forFn contam-
ination by ELISA. The fibrinogen contained 3% by weight; other proteins had <0.1 % Fn
contamination.
Cell Labeling and Solubilization.
￿
Monocytes and PMN were isolated, and monocytes
were cultured as described(4, 6, 7, 19). For cell surface labeling, 30-100 x 106cells were
washed twice in PBS and surface iodinated by chloroglycoluril (22) in the presence of 25
jiM NPGB for 30 min at 0°C. After washing in PBS containing 2 mM KI, cells were
washed and then incubated for 15 min in PBS containing 10 mM iodoacetamide. Cells
were solubilized in buffer A. Aftersolubilization, the suspension was centrifuged at 14,000
gfor 10 min and the pellet was discarded.
Affinity Chromatography.
￿
The surface-labeled, solubilized cells were incubated with 2
ml of affinity-ligand Sepharose overnight at 4'C, after which the Sepharose was poured
into a column, washed with buffer B, and then eluted with either one column volume ofbuffer B containing 1 mg/ml GRGDSP or one column volume of buffer C . Eluted
radioactivity was pooled, concentrated in a YM-30 Centricon apparatus (Amicon Corp .,
Danvers, MA), and analyzed by SDS-PAGE. Careful comparison of the bands seen on
SDS-PAGE showed that identical molecules were visualized from both PMN and mono-
cytes after elution by the two different methods . Therefore, most experiments were done
using buffer C for elution .
Western Blots.
￿
Crude membrane fractions were prepared from PMN and monocytes
by sonication, and collected by centrifugation at 100,000 g. These membranes were
solubilized directly in SDS-PAGE sample buffer without reduction, and Western blots
were performed as described (23) .
Fluorescent Flow Microcytometry. Cells were stained with either mouse mAbs and
fluorescent F(ab')2 anti-mouse Ig (Tago, Inc., Burlingame, CA) or with rabbit polyclonal
antibodies and fluorescent anti-rabbit Ig (Miles-Yeda, Rehovot, Israel), as described (24) .
Nonspecific fluorescence was assessed by using the monoclonal anti-human IgG HG-11
or preimmune rabbit IgG as the primary antibody . Cells were analyzed on a FACS IV ;
25 X 10 , cells were analyzed per point .
Phagocytosis Assays.
￿
Phagocytosis of sheep erythrocytes coated with Cab (EC3b) was
done by a minor modification of our previously described method (16, 19) . Proteins and
peptides were adhered to wells ofLabtek chambers using poly-L-lysine and glutaraldehyde,
as described (25), rather than passive adherence . With this procedure, even peptides that
do not usually bind to uncoated surfaces can be made to adhere to the Labtek chambers .
The presence of bound ligand on the Labtek chambers was confirmed using relevant
antiprotein or antipeptide antibodies and an ELISA technique .
Elution ofSpecific Proteinsfrom Affinity Sepharose Columns.
￿
The elution profile
ofradioactivity from the derivitized Sepharose columns is shown in Fig . 1 . EDTA
eluted specific peaks from Sepharose derivitized with either the 110-kD CBD of
Fn or the synthetic peptide . When bufferA was altered to include 10mM EGTA
and 4 mM MgC12, no EDTA-elutable radioactivity bound to the column (data
not shown) . This suggests that phagocyte Fn receptors require Ca21 for ligand
recognition . When surface-labeled solubilized monocytes were chromatographed
in buffer A, SDS-PAGE of the radioactivity eluted with either GRGDSP or
buffer C revealed distinct proteins binding to the two different affinity columns
(Fig . 2) . Two bands were eluted from CBD-Sepharose with apparent molecular
weights of 150 X 10 3 and 130 X 103. Upon reduction with DTT the two bands
became one broad band at M, 135 X 103, This is quite similar to the pattern of
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FIGURE 1 .
￿
EDTA elution of ligand-affinity columns . Surface-la-
beled monocytes (top panels) or PMN (bottom panels) were solubi-
lized and chromatographed on either peptide-Sepharose (leftpanels)
or CBD-Sepharose (right panels), as described in Materials and
Methods . A representativeEDTA elution profile from each column
is shown .780
￿
FIBRONECTIN RECEPTORS OF PHAGOCYTES
FIGURE 2 . Monocyte RGD binding proteins . The
eluates from CBD-Sepharose (labeled CBD) and peptide-
Sepharose (labeled RGD) were pooled, concentrated, and
run on 6% SDS-PAGE under nonreducing (left) and
reducing (right) conditions . Two distinct profiles can be
observed . The eluate from CBD-Sepharose shows two
bands, which become one broad band after reduction .
The eluate from peptide-Sepharose shows four bands
which become two after treatment with DTT. Molecular
weight markers (X 10"'): Fn (reduced, 220) ; Cab (unre-
duced, 185) ; Cab a chain (110); C36 ,B chain (75); BSA
(66) . Identical bands were obtained on elution with
EDTA and with GRGDSP .
FIGURE 3 . PMN RGD binding
proteins. (A) The EDTA eluates
from CBD-Sepharose (labeled
CBD) and from peptide-Sepha-
rose (labeled RGD) arecompared.
Prominent bands are seen in spe-
cifically bound material from the
peptide-Sepharose column ; only
faint bands are seen in the eluate
from theCBD-Sepharose column .
In contrast to monocytes, how-
ever, these bands are at identical
M to those in the peptide-Sepha-
rose eluate . (-DTT) Run without
reduction ; (+DTT) eluates run
with reduction . (B) GRGDSP
eluatesfrom CBD-Sepharose and
peptide-Sepharose are compared
under nonreducing conditions
with longer exposure to show M,
identity between the eluates from
the two affinity columns. Molec-
ular weight markers (X 10-') as in
Fig . 2 .
the fibroblast Fn receptor on unreduced and reduced gels (9) . When solubilized
monocytes were chromatographed on peptide-Sepharose, SDS-PAGE of the
eluted proteins revealed four bands at 169, 150, 105, and 90 X 10'MT (Fig. 2) .
Upon reduction, only two bands were observed, at 150 and 105 X 10' M, . No
proteins were eluted from a control BSA-Sepharose column by buffer C (not
shown) . Monocytes cultured in vitro for up to 14 d continued to show these
differences between the proteins eluted from CBD- and peptide-Sepharose .
Alveolar macrophages also had both receptors (data not shown) .
In contrast, when PMN were chromatographed on the affinity matrices, the
bands eluted from the CBD-Sepharose and from the peptide-Sepharose were
identical (Fig. 3) . SDS-PAGE revealed bands ofMr 150, 136, 100, and 90 X 10s .
Upon reduction with DTT, bands were observed at 136 and 105 X 10' . OnceBROWN AND GOODWIN
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FIGURE 4. Two-dimensional SDS-PAGE of mono-
cyte eluate from peptide-Sepharose . Peptide-Sepha-
rose eluate was electrophoresed in two dimensions as
described (38). A portion of the higher mol wt spot
has moved below the diagonal, consistent with the loss
of a disulfide-bonded fragment, seen faintly at the
bottom of the gel . A portion ofthe lower mol wt spot
has moved above the diagonal, consistent with the
disruption of intrachain disulfide bonds .
again, no bands were eluted from BSA-Sepharose under identical conditions. In
some experiments, PMN were treated with 0 .5 pM FMLP before surface iodi-
nation . This treatment did not affect the amount of radioactivity eluted by
EDTA or the apparent molecular weight of the eluted material from either
affinity ligand column . When GRGDSP eluates from affinity columns were
dialyzed to remove peptide, >70% of the eluted material from monocytes and
PMN rebound to the ligand-Sepharose columns . The appearance of this rebound
material on SDS-PAGE was identical to the initially bound receptors shown in
Figs . 2 and 3 . The disappearance of some bands upon reduction from both the
monocyte and the PMN eluates from the peptide-Sepharose column may imply
that in phagocytes not all a and ,B chain disulfide bonds are formed in surface-
expressed Fn receptors . The highest Mr band from both monocytes and PMN,
which disappears on reduction, probably represents a chain that was disulfide
bonded to a 25 X 10sMr chain originally synthesized as the COOH-terminus
extension of the a chain (26) since this is a common feature of the integrin family
(18, 27) . The second band may represent a chain without covalently linked
peptide, so that upon reduction its molecular weight in SDS-PAGE does not
change . Thus, after reduction, both forms of the a chain run at the same M,. on
SDS-PAGE . The two lower bands could represent isoforms of the Fn receptor ,Q
chain with and without intrachain disulfide bond formation . When all disulfide
bonds are disrupted by DTT, both forms migrate at the same M,, characteristic
of the higher band on unreduced gels . Two dimensional SDS-PAGE, in which
the first dimension was run unreduced and the second dimension reduced, is
consistent with this interpretation (Fig . 4) . Although the fourbands are not well
resolved, a portion of the a chain band has moved below the diagonal, consistent
with loss of a small fragment, which is faintly visible at the bottom of the gel . A
portion of the ,8 chain band has risen above the diagonal, consistent with
reduction of intrachain disulfide bands . This heterogeneity in disulfide formation
in the molecules eluted from peptide-Sepharose was a frequent finding in both
PMNand monocytes, but occasionally did not occur (Fig . 3B) . The heterogeneity782
￿
FIBRONECTIN RECEPTORS OF PHAGOCYTES
FIGURE 5 .
￿
IB-4 does not recognize thePMN Fn receptor . Solubilized
surface-labeled PMN were immunoprecipitated with IB-4 or the anti-
HLA antibody W6/32 as a control . The supernatant from the immu-
noprecipitation was chromatographed on peptide-Sepharose and the
GRGDSP eluates were electrophoresed. IB-4 did not remove receptor
from the solubilized PMN . Molecular weight markers (x 10-9 ) as in
Fig . 2 .
was not influenced by omission of iodoacetamide from the washing or solubiliza-
tion buffers, was unaffected by whether elution from the peptide-Sepharose was
with GRGDSP or EDTA, andwasnever seen with platelets, with the fibroblastlike
receptor from monocytes (Fig . 2 and Fig . 6, below), or with the vitronectin
receptor of placenta (data not shown) . These data demonstrate that monocytes
have RGD receptors that differ in their affinities for synthetic peptide and the
Fn CBD, while PMN show no evidence of a fibroblastlike receptor with high
affinity for CBD-Sepharose . Moreover, the PMN and monocyte receptors from
the synthetic peptide Sepharose may be distinct, since their a chains differ inMr
after reduction .
Phagocyte RGD Receptors Are Distinct from p(150,95) and Platelet gpIIb/IIIa.
Because of the similarity inMr of the monocyte and PMN molecules eluted from
peptide-Sepharose to the knowncell surface protein p(150,95) (28), we examined
whether these molecules were identical or whether some of the bands eluted
from peptide-Sepharose could represent p(150,95) . p(150,95) is a member of a
family of proteins, including Mac-1 and LFA-1, that share a common a chain .
We used anmAb to this a chain, IB4, to immunoprecipitate all members of this
family from solubilized surface-labeled PMN. The remaining supernatant was
then chromatographed on peptide Sepharose, and radiolabeled protein eluted
with GRGDSP was quantitated and run on SDS-PAGE (Fig . 5) . There was no
difference in quantity of receptor eluted or in its appearance on SDS-PAGE
between PMN lysates precleared with IB4 and those precleared with the control
anti-HLA class I antibody W6/32 . The IB4 immunoprecipitation was complete
as assessed by the appearance ofa typical immunoprecipitation pattern on SDS-
PAGE and the inability of a second incubation with IB4 to immunoprecipitate
further material (data not shown) .
The (3 chain of the platelet Fn receptor, gp Ilb/I1Ia, has a molecular weight
of 90-95 x 103 as well, so we next examined whether the monocyte and PMN
synthetic peptide receptors were identical to gp IIb/I1Ia . For this purpose,
monocyte, PMN, and platelet receptors eluted from peptide-Sepharose were
compared by SDS-PAGE . As shown in Fig. 6, the a chains of the three receptorsBROWN AND GOODWIN
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FIGURE 6. RGD receptors on monocytes,
platelets and PMN. The EDTA eluates from
peptide-Sepharose of surface labeled mono-
cytes, platelets, andPMN are compared under
nonreducing (-DTT) and reducing (+DTT)
conditions . While the ,B chains of the Fn recep-
tors of the three cell types align, the monocyte
and PMN a chains do not align with gp IIb, the
platelet Fn rece~tor a chain . Molecular weight
markers (X 10- ) as in Fig. 2.
had similar M,, when compared on reduced gels, although the monocytes and
PMN showed heterogeneity in their a chain bands on nonreduced gels . On the
other hand, the a chains of the monocyte and PMN receptors, which seem to
have the same molecular weight, are quite distinct from gp Ilb . The M,. of the
monocyte a chain after reduction is 150 X 10s, which is significantly greater
than the platelet gp IIb (Fig . 6) or the a chain of the vitronectin receptor from
fibroblasts, which has a ,B chain very similar to the platelet receptor component
gp IIIa (29) . To further investigate the relationship between gp IIb and the
monocyte and PMN RGD receptors, we examined the binding of the gp IIb-
specific mAb PMI-1 (30) . PMI-1 bound minimally to monocytes and did not bind
to PMN, as assessed by fluorescent flow cytometry (Fig. 7) . This is further
evidence that the monocyte and PMN Fn receptors are not identical to gp
IIb/IIIa . To assess whether the minimal binding of PMI-1 to monocytes repre-
sented platelet contamination or crossreactivity with monocyte molecules, two
experiments were performed . First we examined the binding of another anti-
platelet monoclonal, 7G2, to monocytes and PMN. This monoclonal recognizes
an as yet incompletely characterized antigen on platelets. It does not bind to
monocytes or PMN (Fig . 8), demonstrating that there is no significant contami-
nation of these cells by adherent platelets. Second, we examined the CBD- and
peptide-Sepharose binding molecules from the monocytic cell line U937 (Fig. 9) .
All four monocyte cell surface bands eluted by EDTA from peptide-Sepharose
were also found on U937, again showing that none of these bands arise from
unrecognized platelet contamination . Moreover, PM 1-1 also bound minimally to
U937, as assessed by FACS, suggesting that PMI-1 may crossreact slightly with
monocyte RGD receptors . When polyclonal anti-gp IIb/IIIa was used to stain
monocytes and PMN for fluorescent fluorocytometr)~ it did bind to the phago-
cytes (Fig . 10). Western blots were used to further analyze the binding of this
antiplatelet antibody to phagocytes . As shown in Fig . 11, the polyclonal anti-
Ilb/IIIa recognized both forms of the ,Q chains of the peptide-Sepharose recep-
tors, but only minimally crossreacted with the a chains . This polyclonal antibodyE
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FIGURE 7. Fluorescent flow cy-
tometric analysis of platelets,
monocytes, and PMN usingPMI-
1. Binding of the gp IIb-specific
mAb PMI-1 to platelets (top),
monocytes (middle), and PMN
(bottom) was analyzed by FACS.
Cells stained with PMI-1 are
shown in the shaded contours,
while those stained with a nega-
tive control antibody (HG-11)and
leukocytes stained with apositive
control antibody (IB-4) areshown
in unshaded contours. Only plate-
lets bind PMI-1.
recognizes both a and IQ chains of the gpIIb/IIIa complex (31); in our laboratory,
Western blot analysis of this antibody on platelets shows a chain staining to be
^-80% as intense as # chain staining (data not shown). Taken together, these data
suggest that both monocytes and PMN have receptors for the synthetic RGD-
containing peptides that are distinct from previously described receptors for
these peptides and from previously described phagocyte cell surface antigens.
Thesephagocyte receptors do show structural similarity to the platelet gpIIb/IIIa
complex, primarily in the ,B chain.
The Synthetic Peptide Receptor Is Involved in Enhancement of Phagocytosis.
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FIGURE 8 . mAb 7G2 binds to
platelets but not monocytes or
PMN. Platelet adherence to pu-
rified monocytes and PMN was
assessed with mAb 7G2 . 7G2
binds strongly to plateletsbutnot
at all to monocytes or PMN, dem-
onstrating that platelet contami-
nation of these cell preparations
is below the level of detection .
Because of the existence of two potential Fn receptors on monocytes, we sought
to determine which receptor was involved in phagocytosis enhancement. To do
this, we used the differences in specificity of the two receptors to design ligands
that would preferentially interact with one of the receptors . When surfaces were
coated with the chymotryptic cell binding fragment of Fn, which binds prefer-
entially to the fibroblastlike receptor, no phagocytosis enhancement occurred
(Fig . 12) . In contrast, when surfaces were coated with the synthetic peptide,
cultured monocytes efficiently ingested Cab-opsonized erythrocytes . These data
confirm previous reports (19, 32) and suggest that the synthetic peptide receptor786
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FIGURE 9 . Affinity chromatography of surface-labeled U937 cells .
Solubilized U937 were chromatographed as described above on CBD-
Sepharose (left lane) or peptide-Sepharose (right lane) . SDS-PAGE was
performed under nonreducing conditions. All bands eluted from sur-
face-labeled monocytes are also present on U937 cells .
is the more important cell surface molecule involved in phagocytosis enhance-
ment by Fn . We also tested whether this receptor might have affinity for other
RGD-containing ligands, as does the platelet Fn receptor, gp IIb/11Ia . As shown
in Fig . 12, the RGD-containing molecules fibrinogen, collagen type IV, and
vitronectin also enhanced phagocytosis ofEC3b . In contrast, complement factor
B and vWF, both ofwhich also contain the RGD sequence, did not .
Discussion
Work over the past few years has shown that attachment to Fn can exert an
important regulatory influence on the phagocytic function ofhuman monocytes,
PMN, and monocyte-derived macrophages in vitro. Thus, the biochemical and
cell biologic characteristics of thereceptors for Fn on these cells are ofimportance
to the understanding of the regulation of phagocyte function . Fn receptors on a
variety of cells bind to the amino acid sequence RGD, so we have characterized
the RGD receptors on human phagocytes . To do this, we exploited the fact that
ligand bindingbyRGDreceptors requires Ca" . Elutionof ligand affinity columns
by EDTA gave identical results for phagocytes as did elution by previously
described methods using synthetic peptides (9,10) . The first interesting finding
was that monocytes have two distinct receptors that recognize RGD, while PMN
have only one. The two monocyte receptors can be distinguished structurally
and functionally on the basis of their ability to bind to a chymotryptic fragment
of Fn that contains the RGD sequence and to a synthetic decapeptide that is
based on the Fn sequence around the RGD tripeptide . The monocyte receptor
that binds to the chymotryptic Fn fragment can be eluted with either GRGDSP
or EDTA and resembles the Fn receptor of fibroblasts, osteosarcoma cells,
erythroid cells, and myoblasts . Because it seems less important for mediation of
phagocytosis enhancement, we have not characterized it further here . However,
this receptor may be important in mediating other monocyte responses to Fn,
such as chemotaxis . Relatively large Fn fragments mediate the chemotaxis ofC
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monocytes but not PMN (33). This biological activity is consistent with both the
cell distribution of the fibroblastlike receptor and its ability to bind to RGD
within large enzymatic fragments ofthe Fn molecule.
The second RGD receptor from phagocytes differs from the fibroblastlike
receptor both structurally and functionally, since it has aa chain that has a 35 x
103 M, on unreduced SDS-PAGE and is the receptor that mediates phagocytosis
enhancement. Moreover, its ligand specificity is different since it binds to the
synthetic decapeptide, but binds poorly to the cell binding domain of Fn as it is
expressed in the chymotryptic Fn CBD. In structure, this receptor resembles two788
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Western blot of monocyte and PMN membranes with
polyclonal anti-gpIIb/IIIa . Crude monocyte and PMN membranes
were electrophoresed in 6% SDS-PAGE and analyzed with polyclonal
anti-gpIIb/IIIa by Western blotting. Two dark bands are seen in each
lane which correspond in molecular weight to the two forms of the #
chain seen in Figs . 2 and 3 . The a chains of the monocyte and PMN
receptors stain only minimally with the polyclonal antibody . Markers
at right correspond to the molecularweights of the bands recognized
by Mo-l (Mac-1 a chain, upper mark) and by IB4 (Mac-1 ,B chain,
lower mark) . Molecular weight standards (X 10-s ) are myosin heavy
chain (200), phosphorylaseB (97.4), BSA (68), andOVA (43), from a
prestained molecular weight kit (Bethesda Research Laboratories,
Gaithersburg, MD) electrophoresed and transferred with the mem-
branes .
-moo f~
- ~
￿
c a m
￿
°'rn m
aH
Q
￿
a v Z o
c < < c~ 0 Z 3 m
FIGURE 12 . Phagocytosis enhancement by
RGD-containing peptides . The ability of a va-
riety of RGD-containing molecules to increase
phagocytosis of complement-coated erythro-
cytes is shown . Fn, CYAVTGRGDS (Fn-pep-
tide), fibrinogen (FGN), collagen type IV, and
vitronectin (VN) all enhanced phagocytosis by
monocytes cultured in vitro for 5 d; the chy-
motryptic cell-binding domain of Fn (Fn-CBD),
non Willebrand'sfactor (vWF)andcomplement
Factor B (FB) did not .
previously described cell surface molecules, the Fn receptor from platelets, gp
IIb/IIIa, and the p(150,95) member of the Mac-1, LFA-1 family . However,
experiments using the antibody IB4, which recognizes the 0 chain of p(150,95),
showed that this RGD receptor was not in the Mac-1 family . The phagocyte
synthetic peptide receptor seemed to have greater homology to gp IIb/IIIa, since
it could be recognized by polyclonal antibodies to the platelet complex . However,
further analysis showed that the homology between the phagocyte receptors and
gp IIb/IIIa was almost completely limited to the /3 chain and that the a chains
were distinct . The phagocyte peptide-Sepharose binding molecules are also
structurally distinct from the vitronectin receptor of fibroblasts . Moreover, the
phagocyte molecules seem to have a broader specificity for RGD-containing
proteins than the vitronectin receptor. This suggests the possibility that this
phagocyte receptor is a third member of the family of gp 11b/111a and the
vitronectin receptor, which are believed to have identical ,Q chains but distinct a
chains (29).
Another interesting difference between this receptor on phagocytes and other
described Fn receptors is the apparent heterogeneity of the a and 0 chains onBROWN AND GOODWIN
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unreduced gels. Since this heterogeneity disappears on reduction, it likely reflects
the fact that not all receptor molecules have complete disulfide bond formation.
The evidence that this heterogeneity is not an artifact of receptor isolation is
that: (a) elimination or inclusion of iodoacetamide made no difference to the
appearance of heterogeneity; (b) heterogeneity was seen after elution with both
EDTA and GRGDSP; (c) neither the fibroblastlike receptor from monocytes nor
the platelet receptor isolated on peptide-Sepharose showed heterogeneity; and
(d) heterogeneity was present in the ,B chain of the receptor on Western blots of
monocytes and PMN without any isolation procedures. The fact that these
incompletely disulfide-bonded molecules bind to peptide-Sepharose suggests that
their affinity for RGD is not markedly different from those molecules with
complete disulfide bond formation.
Hosein and Bianco (34) have reported a monoclonal antibody (A6F10) against
the monocyte Fn receptor that recognizes a 110 X 10s Mr band on Western blots
both with and without reduction. This M,. is consistent with the incompletely
disulfide-bonded molecules in the ,# chain of the Fn receptor that binds to
peptide-Sepharose. A6F10 blocks monocyte binding to Fn-coated surfaces (34),
and the binding of Fn-coated microspheres to monocytes and PMNs (8), which
suggests that the phagocyte receptor molecules without intrachain disulfide bonds
exist and retain ligand specificity in the cell membrane as well as in detergent
extracts of monocytes and PMN. An mAb that binds to both gpIIb/IIIa and to
PMN and monocytes has been reported to inhibit the binding of Fn-coated
particles to these cells (35). These data are also consistent with our own that
there is homology between gpIIb/IIIa and the phagocyte Fn receptors. While
the binding site for this monoclonal has not been localized, our data would
suggest that it is in the ,Q chain of the receptor.
Finally, our data suggest that this phagocyte-specific, synthetic peptide binding
receptor generates the signal for enhanced phagocytosis. Phagocytic assays
showed that the synthetic peptide will enhance phagocytosis, but the chymotryp-
tic Fn fragment will not, in agreement with previous reports (19, 32). A6F10
also blocks phagocytosis enhancement by Fn, which is consistent with the hy-
pothesis that it binds to the ,B chain of this Fn receptor. The ability of fibrinogen,
vitronectin, and collagen type IV to enhance phagocytosis suggests that this
receptor may recognize a number of different ligands that contain the RGD
sequence. This ability to bind multiple molecules that contain RGD is also a
property of gp Ilb/IIIa (10). However, in our assays, vWF did not enhance
phagocytosis, while it does bind to gp IIb/IIIa, which suggests that the monocyte
RGD receptor is different from gp IIb/IIIa in ligand specificity as well as
molecular weight.
Thesedata leave unanswered the interesting problem of why resting monocytes
will enhance phagocytosis in response to Fn, but PMN require the combined
signal of Fn and an additional agent such as FMLP or C5a. The synthetic peptide
receptor, which is necessary for phagocytosis enhancement, is present on both
cell types, and is clearly present on the PMN plasma membrane without FMLP
stimulation. One possible explanation for the difference in biological response is
that the second RGD receptor on monocytes does participate in phagocytosis
enhancement, perhaps by altering Fn conformation to make a more effective790
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ligand for the synthetic peptide receptor. We believe that this is unlikely because
FMLP treatment of PMN does not induce expression of this second receptor on
the plasma membrane, although it does induce phagocytic responsiveness to Fn.
A second possible explanation is that the receptors of PMN and monocytes,
although similar on SDS-PAGE, actually have distinct sequences. The role of
FMLP might then be to bring a phagocytosis-enhancing monocytelike receptor
to the PMN plasma membrane, as it does for complement receptors (36, 37).
However, FMLP does not alter Fn binding to PMN (6), nor did we find increased
binding to peptide-Sepharose columns after FMLP treatment of PMN in the
present experiments. This makes the existence of an intracellular expressible
pool of Fn receptors in PMN less likely. Finally, it is possible that the Fn receptor
of the two cell types is associated with different signal transduction mechanisms
and that FMLP alters the association of the PMN Fn receptor with intracellular
effector systems. We currently favor this possibility to explain the difference in
biological effect of Fn on PMN and monocytes.
Summary
We have defined the cell surface molecules of human monocytes and PMN
that bind to the chymotryptic cell binding domain of Fn and to a synthetic
peptide, KYAVTGRGDS, based on the sequence of Fn, by affinity chromatog-
raphy. Monocytes express two receptors that differ in their affinity for CBD-
Sepharose and peptide-Sepharose, but that both recognize the RGD sequence.
Only a single receptor is purified from PMN, which resembles the monocyte
surface molecule that binds to peptide-Sepharose . These receptors are not part
of the Mac-1, LFA-1, p(150,95) family, but do have homology to the platelet Fn
receptor, gpIIb/IIIa. Interestingly, the antigenic crossreactivity between
gpIIb/IIIa and the phagocyte receptors purified on peptide-Sepharose is largely
in the 0 chain of the receptors. The a chains appear to be distinct, based on
molecular weight, antigenic analysis, and ligand specificity. This receptor also
seems to be the surface molecule on monocytes that is critical for phagocytosis
enhancement by Fn .
Thus, we have defined the phagocyte Fn receptor that transduces the signal
for increased phagocytosis by monocytes; it may be a third member of a family
of adhesion molecules that includes the gpIIb/IIIa of platelets and the vitronectin
receptor of fibroblasts.
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